I think they are contrasting . I beleivr MRTX has more potential utilizjng assay screening in early stage trials. I wish cldx would have done better job on validating more precise gentic populations for trials. I think theh optrd for throw all the darts and hop one sticks
excactly hence why institutional % is so low and the ones who are involved are short sellers. Well put
this was failed out of the gate. any form for doxorubicin has failed . More chemo equals more withrdrawals. and aldo was at 350 to 250 dose equiv of dox. If the drug had any chance it was at the same or lower dosage than 250. if you could achieve the same outcome with less side effects you have an apporoval . So prelim data showed cherry picked cases. Look they had clinical holds on the trial what did you expect. It was a p & D . anyone with half a brain would realize that this is not where cancer treatment is going . CAR T , ASSAY screening , ADC, Immune therapies and low dose short interval chemo is far better than aldo. People who have cancer sometimes grasp at the wrong straws . I feel sorry for people who were treated and died or suffered on CYTR's aldo trial . CEO should be ashamed dispicable fraud out for himself . I never owned this garbage. Sorry to be harsh but companies like this are #$%$. POINT PERIOD END OF STORY
If the science has a high level of efficacy a wise investor would spread to other car t companies. I like Blcm and intrexon as alternates. I am not selling this low nor am I a adding
Biomarin outsourced firdapse in us to cprx. BMRN gained approval in EU. Cprx cretes earnings for bmrn in us once cprx gains approval. Cprx then has cash to fund operations. You may see news of one of theor phase 2 drugs being partnered by another pharma. It is a recipe for big returns . you shouldnr have played cprx into fda review you play in after the fda agrees to secondary small p3 trial . we know 90%of eu approved drugs get fda nod.